EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025

  • ID: 3774586
  • Drug Pipelines
  • Region: Global
  • 55 pages
  • GlobalData
1 of 4

EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025

Summary

The American Thoracic Society (ATS) defines IPF as a chronic, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in older adults. IPF is characterized by variable degrees of inflammation and scarring and is associated with a histologic or radiologic pattern of usual interstitial pneumonia (UIP). IPF is the most common form of idiopathic interstitial pneumonia, having the worst prognosis, and only three to five years of median survival. IPF is more common in men and the incidence and prevalence of IPF typically increases with advancing age.

In the 7MM, Our epidemiologists forecast that the diagnosed incident cases of IPF will increase from 53,139 cases in 2015 to 62,258 cases in 2025, at an Annual Growth Rate (AGR) of 1.72%. The US will have the highest number of diagnosed incident cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest. The diagnosed prevalent cases of IPF will also increase from 118,943 cases in 2015 to 137,984 cases in 2025, at an AGR of 1.60%. The US will have the highest number of diagnosed prevalent cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest.

For this analysis, Our epidemiologists used data from large comprehensive healthcare databases and country-specific studies published in peer-reviewed journals to estimate the diagnosed incident and diagnosed prevalent cases of IPF in addition to sources that provided data for cases confirmed through both biopsy of the lung and HRCT. Diagnosed incident and diagnosed prevalent cases were further segmented by age and sex to provide more detailed characteristics regarding the diseased population. The use of studies with consistent methodology across the 7MM provides a significant measure to compare the underlying burden of IPF across the 7MM. Additionally, Our epidemiologists provided the diagnosed incident and diagnosed prevalent cases of IPF in the 7MM, except Japan, segmented by severity (mild, moderate, and severe) based on GAP index, which can be of importance for predicting the prognosis and course of treatment.

Scope

  • The Idiopathic Pulmonary Fibrosis (IPF) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for IPF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of IPF segmented by sex, age (in five-year increments beginning at 18 years and ending at =85 years), and severity in these markets.
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IPF EpiCast report will allow you to

  • Develop business strategies by understanding the trends shaping and driving the global IPF market.
  • Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IPF therapeutics in each of the markets covered.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Epidemiology
2.1 Risk Factors and Comorbidities
2.2 Global Trends
2.2.1 Incidence
2.2.2 Prevalence
2.3 Forecast Methodology
2.3.1 Sources Used
2.3.2 Forecast Assumptions and Methods
2.3.3 Sources Not Used
2.4 Epidemiological Forecast for IPF (2015-2025)
2.4.1 Diagnosed Incident Cases
2.4.2 Diagnosed Prevalent Cases
2.4.3 IPF Mortality
2.5 Discussion
2.5.1 Epidemiological Forecast Insight
2.5.2 Limitations of the Analysis
2.5.3 Strengths of the Analysis

3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head of Healthcare
3.3 About us
3.4 About EpiCast
3.5 Disclaimer

1.1 List of Tables
Table 1: Risk Factors and Comorbidities of IPF
Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IPF
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF
Table 4: 7MM, except Japan, Sources Used to Forecast Severity Segmentation of Diagnosed Incident Cases and Diagnosed Prevalent Cases of IPF
Table 5: 7MM, Sources Used to Forecast IPF Deaths
Table 6: 7MM, Sources Not Used in the Epidemiological Analysis of IPF
Table 7: 7MM, Diagnosed Incident Cases of IPF, Ages =18 Years, Both Sexes, N, Selected Years 2015-2025
Table 8: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N (Row %), 2015
Table 9: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages =18 Years, N (Row %), 2015
Table 10: 7MM, Diagnosed Prevalent Cases of IPF, Ages =18 Years, Both Sexes, N, Selected Years 2015-2025
Table 11: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N (Row %), 2015
Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages =18 Years, N (Row %), 2015
Table 13: 7MM, IPF Deaths, Ages =18 Years, Both Sexes, N, Selected Years 2015-2025
Table 14: 7MM, Age-Specific IPF Deaths, Both Sexes, N (Row %), 2015
Table 15: 7MM, Sex-Specific IPF Deaths, Ages =18 Years, N (Row %), 2015

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of IPF, Ages =18 Years, Both Sexes, N, 2015-2025
Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N, 2015
Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages =18 Years, 2015
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of IPF, Ages =18 Years, N, 2015
Figure 5: US and 5EU, Diagnosed Incident Cases of IPF by Severity, Both Sexes, Ages =18, 2015
Figure 6: 7MM, Diagnosed Prevalent Cases of IPF, Ages =18 Years, Both Sexes, N, Selected Years 2015-2025
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N, 2015
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages =18 Years, 2015
Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of IPF, Ages =18 Years, N, 2015
Figure 10: US and 5EU, Diagnosed Prevalent Cases of IPF by Severity, Both Sexes, Ages =18 Years, 2015
Figure 11: 7MM, IPF Deaths, Ages =18 Years, Both Sexes, N, Selected Years 2015-2025
Figure 12: 7MM, Age-Specific IPF Deaths, Both Sexes, N, 2015
Figure 13: 7MM, Sex-Specific IPF Deaths, Ages =18 Years, 2015

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll